Hello,
Welcome to Insider
- A finance whiz thinks he may have solved biotech's clinical trial problem;
- Take a look at the presentation a concierge emergency-care startup used to raise $30 million;
- At least 75 lawmakers bought and sold COVID-related stocks during the pandemic.
If you're new to this
More than 90% of drug trials fail every year. A finance expert wants to help pharma predict when it will happen.
- MIT's Andrew Lo is known for studying Wall Street, but he's turned his attention to
biotech . - He wants to predict which drugs will fail
clinical trials so money and patients' time can be saved. - But experts say his tech needs more work and that getting it wrong may cause harm.
See the 14-slide presentation a members-only concierge emergency-care startup used to raise $30 million in Series A funding
- Sollis
Health is a membership-based concierge emergency-care startup in New York. - It announced its Series A round led by Torch Capital and Denali Growth Partners on Tuesday.
- It wants to add more clinics in existing cities and open new offices in San Francisco next year.
As the pandemic raged, at least 75 lawmakers bought and sold stock in companies that make COVID-19 vaccines, treatments, and tests
- At least 75 federal lawmakers held shares of Moderna, Johnson & Johnson, or Pfizer in 2020.
- Lawmakers' holding stock in these companies has prompted ethical concerns.
- Several other lawmakers traded shares of companies with a direct stake in the pandemic.
More stories we're reading:
- Omicron could make you infectious more quickly than Delta — take a rapid test no earlier than a few hours before heading to a party, experts say (Insider)
- Orthopedic surgery as a specialty continues to have a diversity problem (STAT)
- The famed startup accelerator Y Combinator is wading into the $100 billion psychedelics industry. Here's how 3 psychedelics firms got into the program. (Insider)
- Vaccinators in Peru struggle to get access to remote communities with physical and cultural barriers (NPR)
-Leah